TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02066415

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered once a month subcutaneously by authorized investigational site study staff.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once a month subcutaneously by authorized investigational site study staff.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Study: NCT03303612

Intervention type: DEVICE
Group type: OTHER
Intervention: Pacemaker implant
Description: Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous cardiac monitor
Description: Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;
Study: NCT05605171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction urethrovesical anastomosis.
Description: Rocco stitch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vesicourethral anastomosis.
Description: Standard of care.
Study: NCT01120795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Description: Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Description: Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
Study: NCT01533922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium + olodaterol FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 5 mcg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: Olodaterol 5 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: tiotropium + olodaterol 5 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT04087187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily
Study: NCT01067222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 oral capsules at 10 or 20 or 40 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil oral capsules at 100 or 200 or 400 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, 4 capsules per day
Study: NCT00101907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
Study: NCT01533922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study: NCT03328858

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
Study: NCT00101907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
Study: NCT00675896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Sustained Release
Description: 50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
Study: NCT03968783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monofilament suture
Description: 1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifilament suture
Description: 1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
Study: NCT03412604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
Study: NCT02662179

Intervention type: OTHER
Intervention: Quality of life evaluation
Description: Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.

Intervention type: OTHER
Intervention: Functional decline assessment
Description: Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.

Intervention type: OTHER
Intervention: Physical decline assessment
Description: Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study: NCT00101907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
Study: NCT01184027

Intervention type: BEHAVIORAL
Intervention: nutrition /swallowing intervention
Description: Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
Study: NCT02893800

Intervention type: DEVICE
Group type: OTHER
Intervention: Locating system watch with GPS-technology
Description: Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
Study: NCT02662179

Intervention type: OTHER
Intervention: Cognitive decline assessment
Description: Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study: NCT02634606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Delta Tocotrienols - Low Dose
Description: 250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
Study: NCT03030651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education and Support
Description: Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
Study: NCT03091569

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
Study: NCT03783221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-residue diet
Description: The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
Study: NCT02634606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Delta Tocotrienols - High Dose
Description: 250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
Study: NCT01415206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Staging Health Risk Intervention (S-HRI)
Description: The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
Study: NCT02038049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: Single intravenous infusion of VAY736 (10 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to VAY736
Study: NCT03540329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Osteogenesis distractor
Description: Internal distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Osteogenesis distractor
Description: Internal distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Osteogenesis distractor
Description: Internal distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Osteogenesis distractor
Description: Internal distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Osteogenesis distractor
Description: External distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Osteogenesis distractor
Description: External distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Osteogenesis distractor
Description: External distraction osteogenesis in mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Osteogenesis distractor
Description: External distraction osteogenesis in mandible
Study: NCT00329914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal pessaries, 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pessaries containing peanut oil
Study: NCT03377049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 1 g acetazolamide through a peripheral IV line
Study: NCT02068157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo image-guided I-PDT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV
Study: NCT02191839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Antitrypsin
Study: NCT01890278

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Whole Brain RT
Study: NCT02002689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
Study: NCT02679820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T intrauterine device
Study: NCT02482402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost
Description: Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhalation solution placebo
Study: NCT04221191

Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: DMF as prescribed as standard of care.

Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: DMF as prescribed as standard of care.

Intervention type: OTHER
Intervention: PSP
Description: PSPs is to support patient care.
Study: NCT01496105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT01013363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPod Nano digital music player
Description: Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
Study: NCT00202033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: frequency of self monitoring blood glucose
Description: Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: frequency of self monitoring blood glucose
Description: Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: frequency of self monitoring blood glucose
Description: Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
Study: NCT03546218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application (SPSRS)
Description: Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone Application (YouTube)
Description: Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
Study: NCT02395211

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Description: Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gloreha device
Description: Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
Study: NCT02801890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous injection
Description: Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
Study: NCT04637919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 EV71 A dose
Description: Inactivated vaccine against EV71, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 CVA16 B dose
Description: Inactivated vaccine against CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 Bivalent C dose
Description: Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval
Study: NCT04049929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
Study: NCT02759315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir 450 mg
Description: 450 mg administered as 3 x 150 mg oral tablets
Study: NCT00101907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Study: NCT01333865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated.
Study: NCT03345875

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment
Description: Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
Study: NCT04094662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Description: Mirogabalin tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration